CLOZAPINE-INDUCED AGRANULOCYTOSIS AND THROMBOPENIA IN A PATIENT WITH DOPAMINERGIC PSYCHOSIS

In patients with Parkinson' disease and dopaminergic psychosis, clozap ine treatment is recommended as the drug is free from extrapyramidal s ide effects and does not worsen motor symptoms of the underlying disea se. The use of clozapine, however, is limited due to its hematotoxic s ide effects. For treatment of clozapine-induced agranulocytosis, granu locyte colony-stimulating factors (G-CSF) are recommended. We report t he case of a 72-years-old male patient with clozapine-induced agranulo cytosis and thrombopenia. Neutropenia was successfully treated with G- CSF, but thrombopenia persisted and resolved spontaneously after 14 da ys. Bone marrow toxicity of clozapine is not restricted to white cell maturation, but may also impair thrombocytopoesis.